HK1056830A1 - Mannose as intranasal vaccine adjuvant - Google Patents

Mannose as intranasal vaccine adjuvant Download PDF

Info

Publication number
HK1056830A1
HK1056830A1 HK03107477.4A HK03107477A HK1056830A1 HK 1056830 A1 HK1056830 A1 HK 1056830A1 HK 03107477 A HK03107477 A HK 03107477A HK 1056830 A1 HK1056830 A1 HK 1056830A1
Authority
HK
Hong Kong
Prior art keywords
antigen
mice
llo
mannan
iga
Prior art date
Application number
HK03107477.4A
Other languages
German (de)
English (en)
Chinese (zh)
Other versions
HK1056830B (en
Inventor
Ian Farquhar Campbell Mckenzie
Geoffrey Allan Pietersz
Christina Cheers
John Stambas
Charles Eric Reynolds
Neil Martin O'brien-Simpson
Original Assignee
Igavax Pty Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igavax Pty Ltd. filed Critical Igavax Pty Ltd.
Publication of HK1056830A1 publication Critical patent/HK1056830A1/en
Publication of HK1056830B publication Critical patent/HK1056830B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Claims (10)

  1. Utilisation d'une composition comprenant un antigène et un adjuvant à base de polymère de glucide comprenant du mannose, où ledit polymère
    a) comprend des monomères de mannose oxydés pour produire des groupes aldéhydes, et
    b) est lié de manière covalente à l'antigène ;
    pour la préparation d'un vaccin destiné à une administration intranasale pour générer une réponse immunitaire contre l'antigène comprenant une réponse immunitaire sécrétoire.
  2. Utilisation selon la revendication 1, où la réponse immunitaire comprend une réponse immunitaire humorale.
  3. Utilisation selon la revendication 1 ou la revendication 2, où la réponse immunitaire comprend une réponse d'IgA.
  4. Utilisation selon l'une quelconque des revendications 1 à 3, où la réponse immunitaire comprend une augmentation des taux d'anticorps au niveau de sites mucosaux.
  5. Utilisation selon l'une quelconque des revendications 1 à 4, où la réponse immunitaire comprend une augmentation des taux d'anticorps dans le sérum.
  6. Utilisation selon l'une quelconque des revendications 1 à 5, où la réponse immunitaire comprend une stimulation de médiateurs de l'immunité cellulaire Th1 et/ou Th2.
  7. Utilisation selon l'une quelconque des revendications 1 à 6, où la production d'IgE est réduite ou inchangée.
  8. Utilisation selon l'une quelconque des revendications 1 à 7, où l'antigène est choisi dans le groupe constitué des suivants ou de parties immunogéniques de ceux-ci : pollens, allergènes, bactéries, virus, levures, champignons, protozoaires ou d'autres micro-organismes y compris des agents pathogènes des êtres humains, des animaux et des végétaux.
  9. Utilisation selon la revendication 8, où l'antigène est choisi dans le groupe constitué par le virus de la grippe, l'hémagglutinine de la grippe, Porphyromona gingivalis, des épitopes de protéinases et d'adhésines de Porphyromona gingivalis, Helicobacter pylori, l'uréase de Helicobacter pylori, des rotavirus, la protéine VP5 recombinante de rotavirus, le VIH, la gp120 du VIH, le RSV, des protéines de surface du RSV et des peptides de l'ovalbumine et Listeria monocytogenes, Mycobacterium tuberculosis, Mycobacterium avium, le BCG, la nucléoprotéine de la grippe, des protéines F ou G du virus respiratoire syncytial (RSV), Candida albicans et Chlamydia trachomatis ou la protéine de la membrane externe de celles-ci, la protéine externe de classe 1 de Neisseria meningitidis, la glycoprotéine G de type 1 ou la gp D ou CP27 du virus Herpes simplex, le virus du papillome humain, la glycoprotéine E du virus de l'encéphalite de la vallée de la Murray, des parties antigéniques de ceux-ci et des dérivés de ceux-ci.
  10. Utilisation selon la revendication 8 ou la revendication 9, où l'antigène est choisi dans le groupe constitué d'antigènes du VIH, d'antigènes du paludisme, d'antigènes provenant de micro-organismes qui provoquent des maladies vénériennes, un rhume banal ou la grippe et d'antigènes qui induisent l'asthme.
HK03107477.4A 2000-06-06 2001-06-06 Mannose as intranasal vaccine adjuvant HK1056830B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ7977 2000-06-06
AUPQ7977A AUPQ797700A0 (en) 2000-06-06 2000-06-06 Vaccine
PCT/AU2001/000669 WO2001093912A1 (fr) 2000-06-06 2001-06-06 Vaccin

Publications (2)

Publication Number Publication Date
HK1056830A1 true HK1056830A1 (en) 2004-03-05
HK1056830B HK1056830B (en) 2010-10-22

Family

ID=

Also Published As

Publication number Publication date
AU6365301A (en) 2001-12-17
US8182821B2 (en) 2012-05-22
ATE456958T1 (de) 2010-02-15
AU2007302633A1 (en) 2008-04-03
AU2006222717A1 (en) 2006-10-19
EP1301208B1 (fr) 2010-02-03
EP2066332A1 (fr) 2009-06-10
EP1301208A4 (fr) 2004-11-17
WO2001093912A1 (fr) 2001-12-13
US20040043032A1 (en) 2004-03-04
EP1301208A1 (fr) 2003-04-16
US20110033493A1 (en) 2011-02-10
US20100008951A1 (en) 2010-01-14
AUPQ797700A0 (en) 2000-06-29
DE60141243D1 (de) 2010-03-25
EP2066332A4 (fr) 2012-01-18

Similar Documents

Publication Publication Date Title
US20110033493A1 (en) Vaccine
Hu et al. Immunostimulating complexes (ISCOMs) for nasal vaccination
Holmgren et al. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges
Russell et al. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
Staats et al. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses
Anggraeni et al. Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants
Weltzin et al. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection
Hamajima et al. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response
Po et al. Design and delivery of non-parenteral vaccines.
JP2001509491A (ja) アジュバントとしてモノグリセリドまたはジグリセリドを含む抗原送達系
US20020068090A1 (en) Calcium phosphate particles as mucosal adjuvants
KR100622716B1 (ko) 인터루킨-12 및 허피스 심플렉스 바이러스 항원을포함하는 백신
McGhee et al. The common mucosal immune system: from basic principles to enteric vaccines with relevance for the female reproductive tract
Stambas et al. Oxidised mannan as a novel adjuvant inducing mucosal IgA production
CN102711815B (zh) 用于疫苗的佐剂、包含所述佐剂的疫苗及其用途
Hu et al. Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes
AU2001263653B2 (en) Vaccine
Chin et al. Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants
US20220257752A1 (en) New use of cyclic dinucleotides
Hsieh et al. Intranasal vaccination with recombinant antigen-FLIPr fusion protein alone induces long-lasting systemic antibody responses and broad T cell responses
AU2001263653A1 (en) Vaccine
HK1056830B (en) Mannose as intranasal vaccine adjuvant
Pacheco et al. Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity
WO2008037033A1 (fr) Vaccin contre la grippe constitué d'un mélange de mannane et d'antigène de la grippe

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: JOHN STAMBAS

Free format text: FORMER OWNER(S): THE AUSTIN RESEARCH INSTITUTE, THE UNIVERSITY OF

Owner name: THE AUSTIN RESEARCH INSTITUTE

Free format text: FORMER OWNER(S): THE AUSTIN RESEARCH INSTITUTE, THE UNIVERSITY OF

Owner name: THE UNIVERSITY OF MELBOURNE

Free format text: FORMER OWNER(S): THE AUSTIN RESEARCH INSTITUTE, THE UNIVERSITY OF

Owner name: JOHN STAMBAS TO CHRISTINA CHEERS

Free format text: FORMER OWNER(S): THE AUSTIN RESEARCH INSTITUTE, THE UNIVERSITY OF

Owner name: MELBOURNE

Free format text: FORMER OWNER(S): THE AUSTIN RESEARCH INSTITUTE, THE UNIVERSITY OF

CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: CHARLES ERIC REYNOLDS; NEIL MARTIN O BRIEN-SIMPSON

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140606